Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases

Cancer

Volumn 118, Issue 8, 2012, Pages 2039-2047

  Niikura, Naoki ^a   Liu, Jun ^b   Hayashi, Naoki ^a   Palla, Shana L ^b   Tokuda, Yutaka ^a   Hortobagyi, Gabriel N ^a   Ueno, Naoto T ^a   Theriault, Richard L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

bisphosphonate; bone only metastases; breast cancer; zoledronic acid

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84859645793     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26512     Document Type: Article

References (41)

1. Manders K, van de Poll-Franse LV, Creemers GJ, et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer. 2006; 6: 179.
2. Sherry MM, Greco FA, Johnson DH, Hainsworth JD,. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med. 1986; 81: 381-386.
3. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN,. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986; 58: 2589-2593.
4. Plunkett TA, Smith P, Rubens RD,. Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000; 36: 476-482.
5. Cazzaniga ME, Dogliotti L, Cascinu S, et al. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology. 2006; 71: 374-381.
6. Domchek SM, Younger J, Finkelstein DM, Seiden MV,. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 2000; 89: 363-368.
7. Smalley RV, Scogna DM, Malmud LS,. Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases. Am J Clin Oncol. 1982; 5: 161-166.
8. Coleman RE, Smith P, Rubens RD,. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998; 77: 336-340.
9. Perez JE, Machiavelli M, Leone BA, et al. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncologico Cooperativo del Sur. Am J Clin Oncol. 1990; 13: 294-298.
10. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of 2 randomized, placebo-controlled trials. Cancer. 2000; 88: 1082-1090.
11. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999; 17: 846-854.
12. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335: 1785-1791.
13. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16: 2038-2044.
14. Green JR,. Bisphosphonates: preclinical review. Oncologist. 2004; 9 (Suppl 4): 3-13.
15. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005; 23: 3314-3321.
16. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004; 100: 36-43.
17. Clezardin P,. Anti-tumour activity of zoledronic acid. Cancer Treat Rev. 2005; 31 (Suppl 3): 1-8.
18. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T,. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004; 10: 4559-4567.
19. Neville-Webbe HL, Evans CA, Coleman RE, Holen I,. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006; 27: 92-103.
20. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I,. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008; 100: 1167-1178.
21. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003; 9: 2893-2897.
22. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI,. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001; 84: 1126-1134.
23. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M,. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000; 96: 384-392.
24. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002; 20: 3219-3224.
25. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006; 8: R13.
26. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008; 19: 2007-2011.
27. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C,. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004; 43: 650-656.
28. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008; 3: 228-236.
29. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679-691.
30. Park IH, Ro J, Nam BH, Kwon Y, Lee KS,. Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer. 2009; 9: 154.
31. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003; 83: 803-819.
32. Black MM, Speer FD,. Nuclear structure in cancer tissues. Surg Gynecol Obstet. 1957; 105: 97-102.
33. The World Health Organization. Histological typing of breast tumors. Neoplasma. 1983; 30: 113-123.
34. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
35. Winter MCTH, Burkinshaw R, Beevers SJ, Coleman R,. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumour activity in breast cancer. Cancer Res. 2009; 69: abstr 5101.
36. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11: 421-428.
37. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010; 21: 2188-2194.
38. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005; 97: 59-69.
39. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005; 23: 4925-4935.
40. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE,. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007; 12: 1035-1043.
41. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010; 102: 1099-1105.